FDA Approves Second Humira Biosimilar, Cyltezo FDA Approves Second Humira Biosimilar, Cyltezo

Adalimumab-adbm Cyltezo, from Boehringer Ingelheim, is approved for multiple indications including treatment of adults with moderate-to-severe active rheumatoid arthritis.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news